黄素的抗癌潜力:概述,重点是格雷丁
Francisco Canindé Ferreira de Luna1, Wallax Augusto Silva Ferreira1, Samir Mansour Moraes Casseb2
1Laboratory of Cytogenomics and Environmental Mutagenesis, Environment Section (SEAMB), Evandro Chagas Institute (IEC), BR 316, KM 7, s/n, Levilândia, Ananindeua 67030-000, Brazil.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
黄类化合物,就像类植物中的色素一样,显示出作为抗癌剂的希望. 坦格雷丁表现出抗瘤特性,由于耐药性问题,为新的癌症疗法提供了潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 在瘤学瘤学.
背景情况:
- 黄酸是具有多种药理活动的天然化合物,包括抗氧化,抗炎和抗瘤特性.
- 它们的生物可用性,成本效益和最小的副作用使它们成为癌症治疗开发的有吸引力的候选人.
- 瘤对传统化疗的耐药性需要探索新的治疗策略.
研究的目的:
- 为了回顾果中发现的黄胺 (flavonoid) tangeretin的抗瘤特性.
- 为了突出tangeretin作为细胞毒性抗癌化合物的潜力.
- 讨论其对抗癌症主要特征的活性.
主要方法:
- 本综述综合了有关格雷丁生物活性的现有研究.
- 分析了研究探讨坦格雷丁对各种癌症细胞系的影响的研究.
- 该审查侧重于与癌症特征相关的机制.
主要成果:
- 坦格雷丁在癌症细胞系中表现出显著的抗增殖和亡作用.
- 它表现出抗炎,抗转移和抗血管新生活性.
- 坦格雷丁调节瘤抑制基因表达和表观遗传机制.
结论:
- 坦格雷丁具有广泛的抗瘤特性,向多种癌症特征.
- 它作为一种新型抗癌剂的潜力需要进一步研究药物开发.
- 坦格雷丁可能为癌症治疗策略提供有价值的补充,特别是在耐药性病例中.
相关概念视频
Cancer Prevention
6.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.2K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


